NCT05016687 - First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

March 22, 2022

Study Completion Date

March 22, 2022

Conditions

Pulmonary Disease, Chronic ObstructiveEnterovirus InfectionsRhinovirus

Interventions

DRUG

CUR-N399

CUR-N399 will be administered as oral capsules.

DRUG

Placebo

Placebo capsules matching CUR-N399 will administered.

Trial Locations (1)

CTC Clinical Trial Consultants AB, Uppsala